Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme

Recent Advances: AI in Life Sciences—Reimagining Teams, Technology, and Partnerships

AI in life sciences; generative AI; large language models; team transformation; technology innovation; strategic partnerships; drug discovery; personalized medicine; data integration

Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success

Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Recent Developments in NLP and Generative AI for Life Sciences and Precision Medicine (2025)

NLP; Generative AI; life sciences; precision medicine; healthcare; large language models; multimodal AI; quality management; drug discovery; pharmacovigilance

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry